Summary
We have analyzed whether lymphokine-activated killer (LAK) cells, generated from C57BL/6J (B6) spleen cells at different times after recombinant interleukin-2 (rIL-2) culture, could be heterogeneous in their ability to lyse a variety of tumor targets. When tested 3 days after exposure to 250 U/ml rIL-2 (day-3 LAK cells) a significant lysis was detected with the natural-killer(NK)-sensitive YAC lymphoma, the NK-resistant P815 mastocytoma, three different syngeneic melanomas and a syngeneic fibrosarcoma (group 1 targets), whereas no lysis was observed with a reticulum cell sarcoma, two different lymphomas or concanavalin A blasts, all of B6 origin (group 2 targets). LAK cells cultured for 5 days, however, lysed group 2 targets and showed a parallel increase of cytotoxic activity against group 1 targets. At day 7, LAK activity declined on all targets examined. In cold-target inhibition studies, the lysis of group 1 tumor targets by day-3 or day-5 LAK cells could be inhibited only by group 1 and not by group 2 unlabelled tumor cells. All group 1 tumors could effectively compete each other. Conversely, the lysis of group 2 tumor targets by day-5 LAK cells was inhibited by both group 1 and group 2 targets. These data indicate the presence of separate LAK effectors that appear to arise with different time kinetics and have different recognition structures. In vitro antibody depletion at the effector level showed that day-3 LAK cells with cytotoxic activity against group 1 tumors were ASGM1+. Day-5 LAK cells included both ASGM1+ and Lyt2+ effectors and both populations, although to a different extent, contributed to the lysis of all targets. Our results indicate that LAK cells are functionally heterogeneous. This heterogeneity is defined by their susceptible target cells and cannot be ascribed to different (Lyt2+ versus ASGM1+) lineages.
Similar content being viewed by others
References
Ballas ZK, Rasmussen W, Van Otegham JK (1987) Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulation. J Immunol 138: 1647
Chong A S-F, Aleksijevic A, Scuderi P, Hersh EM, Grimes WJ (1989) Phenotypic and functional analysis of lymphokineactivated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets. Cancer Immunol Immunother 29: 270
Damle NK, Doyle LV, Bradley EC (1986) Interleukin 2 activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol 137: 2814
Ferrini S, Moretta L, Pantaleo G, Moretta A (1987) Surface markers of human lymphokine-activated killer cells and their precursors. Analysis at the population and clonal level. Int J Cancer 39: 18
Formelli F, Rossi C, Supino R, Parmiani G (1986) In vivo characterization of a doxorubicin resistant B16 melanoma cell line. Br J Cancer 54: 223
Gambacorti-Passerini C, Rivoltini L, Supino R, Rodolfo M, Radrizzani M, Fossati G, Parmiani G (1988) Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2 activated lymphocytes. Cancer Res 48: 2372
Grimm EA (1985) The human lymphokine-activated killer cell system. V. Purified recombinant interleukin-2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol 94: 568
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823
Grimm EA, Ramsey A, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA (1983) Lymphokine-activated killer phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus derived lymphocytes and natural killer cells. J Exp Med 157: 884
Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E (1989) Generation and characterization of purified lymphokine-activated killer cells in mice. J Immunol 142: 1748
Itoh K, Tilden AB, Kumagai K, Balch CM (1985) Leu 11+ lymphocytes with natural killer activity are precursors of recombinant interleukin 2 (rIL2) induced activated killer cells. J Immunol 134: 802
Kalland T, Belfrage H, Bhihdivala P, Hedlund G (1987) Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK and T-like cells. J Immunol 138: 3640
Laybourn KA, Hiserodt JC, Varani J (1989) Laminin receptor expression on murine tumor cells: correlation with sensitivity to natural cell-mediated cytotoxicity. Int J Cancer 43: 737
Lefor AT, Eisenthal A, Rosenberg SA (1988) Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor allogeneic blasts, and modified syngeneic blasts. J Immunol 140: 4062
Morris DG, Pross HF (1989) Studies of lymphokine activated killer (LAK) cells. Evidence using novel monoclonal antibodies that most LAK precursor cells share a common surface marker. J Exp Med 169: 717
Ortaldo JR, Mason A, Overton R (1986) Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 164: 1193
Phillyps JH, Lanier LL (1986) Dissection of the lymphokineactivated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164: 814
Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA (1985) Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst 75: 67
Rosenberg SA (1986) Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 75: 595
Rosenberg SA, Lotze MT, Muul LM, Chong AE, Avis FP, Leitman S, Linehan WH, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889
Rosenstein M, Yron I, Kauffmann Y, Rosenberg SA (1984) Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 44: 1946
Salup RR, Mathieson BJ, Wiltrout RH (1987) Precursor phenotype of lymphokine-activated killer cells in the mouse. J Immunol 138: 3635
Schwartz RE, Hiserodt JC (1988) The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu 19+/CD3− natural killer lymphocytes. J Immunol 141: 3318
Sensi ML, Carbone G, Parmiani G (1980) Original H-2d and alien H-2K like antigens of a BALB/c fibrosarcomas as defined by in vitro and in vivo studies of cell-mediated immunity. Eur J Immunol 10: 671
Silveinnoinen O, Vakkila J, Hurme M (1988) Accessory cells, dendritic cells, or monocytes are required for the lymphokineactivated killer cell induction from resting T cell but not from natural killer cell precursors. J Immunol 141: 1404
Suttles J, Schwarting GA, Stout RD (1986) Flow cytometric analysis reveals the presence of asialo-GM1 on the surface membrane of alloimmune cytotoxic T lymphocytes. J Immunol 136: 1586
Tilden AB, Itoh K, Balch CH (1987) Human lymphokine activated (LAK cells): identification of two types of effector cells. J Immunol 138: 1068
Traversari C, Carbone G, Della Torre G, Bergomi M, Parmiani G, Sensi ML (1989) Expression of retrovirus related cytotoxic T lymphocyte and transplantation-defined antigens in NIH-3T3 transfectants after a single passage in nude mice. J Immunol 142: 2887
Verret CR, Firmenich AA, Kranz DM, Eisen HN (1987) Resistance of cytotoxic T lymphocytes to the lytic effects of their toxic granules. J Exp Med 166: 1536
Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW, Hiserodt JC (1988) Lymphokineactivated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Cancer Res 48: 884
Yang JC, Mulé JJ, Rosenberg SA (1986) Murine lymphokineactivated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. J Immunol 137: 715
Yun Y-S, Hargrove ME, Ting C-C (1988) Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody. J Immunol 141: 1390
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sensi, M., Grazioli, L., Rodolfo, M. et al. Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors. Cancer Immunol Immunother 31, 37–43 (1990). https://doi.org/10.1007/BF01742493
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01742493